Stocks in news: IRFC, Voltas, IDFC First Bank, Alembic Pharma, Lupin

Markets remained under pressure on Tuesday and traded sharply lower amid weak global cues. Technically, analysts say the Nifty has once again retested the crucial support near the 25,400 zone, and a decisive break below this level could trigger the next leg of the decline towards 25,245, which coincides with the 200 DEMA, followed by a major support area around 25,100, marked by a gap on the daily chart.

In today's trade, shares of IRFC, Voltas, IDFC First Bank, Alembic Pharma, Lupin among others will be in focus due to various news developments.

IRFC

Government will sell up to 4% stake in Indian Railway Finance Corporation (IRFC) via an offer for sale (OFS) which opens on Wednesday for non-retail investors while retail investors will be able to place bids on Thursday. The government has offered to divest 2% equity in IRFC with an additional 2% as green shoe option.

Voltas
Voltas is expecting air conditioner prices to go up by 5-15% this year owing to increase in copper prices and the rupee weakening against the dollar, Managing Director Mukundan Menon said. The country's leading air-conditioning manufacturer, having a market share of around 18% in the domestic market, expects domestic AC sales to grow by 15-20% in 2026 over last year which turned out to be bad for the entire industry.

Alembic Pharma
Alembic Pharmaceuticals said it has received approval from the US health regulator to market generic antifungal medication. The company has received final approval from the US Food & Drug Administration (USFDA) for Efinaconazole Topical Solution (10%).

IDFC First Bank
The Haryana government on Tuesday constituted a high-level committee to examine the unauthorised transfer of funds from IDFC First Bank and AU Small Finance Bank and to review the state’s banking policy, according to an official order issued by the Personnel Department.

Lupin
Lupin announced that it has received approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Brivaracetam Oral Solution 10 mg/mL. Brivaracetam is the bioequivalent to Briviact Oral Solution of UCB, Inc and is indicated for the treatment of partial-onset seizures in patients 1 month of age and older.